Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
EPPIK (FSGS & MCD)
The EPPIK Clinical Study for Children with FSGS and MCD
Breve descripción
The EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 1-17 with enrollment currently open to patients 2 to 7 years. Indications include: • Focal segmental glomerulosclerosis (FSGS) • Minimal change disease (MCD) See also the EPPIK Clinical Study for Children with IgAN, IgAV, and Alport Syndrome.
Médico del ensayo/Coordinador del estudio
Amy Hanson
Correo electrónico Número de teléfono 612-626-4424Nombre del sitio
University of Minnesota
Department of Pediatrics, Riverside Professional Building, Suite 535, 606 24th Avenue South, Minneapolis, MN 55454
Matrícula estimada
The entire EPPIK study (including FSGS, MCD, IgAN, IgAV and Alport Syndrome) will enroll approximately 57 children.
Fecha estimada de finalización
To be determined
Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
EPPIK (FSGS & MCD)
The EPPIK Clinical Study for Children with FSGS and MCD
Breve descripción
The EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 1-17 with enrollment currently open to patients 2 to 7 years. Indications include: • Focal segmental glomerulosclerosis (FSGS) • Minimal change disease (MCD) See also the EPPIK Clinical Study for Children with IgAN, IgAV, and Alport Syndrome.
El ensayo es para personas con
For children ages 1-17 with:
• Focal segmental glomerulosclerosis (FSGS)
• Minimal change disease (MCD)
Objetivo del estudio
The goals of the study are to evaluate the safety and effectiveness of sparsentan on children with FSGS, MCD, IgAN, IgAV and Alport syndrome.
Qué implica para el paciente?
Patients will participate for about 2 years and 3 months and will receive sparsentan.
Sobre el medicamento o la intervención
Participants receive sparsentan, the investigational drug, taken as a liquid by mouth.